Skip to main content

Table 3 Univariate and multivariate analyses of survival (Cox’s proportional hazards regression models)

From: SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma

Factor Univariate Multivariate
P-value HR (95% CI) P-value
OS
Age ( ≥65/<65) 0.0242a 4.1216 (1.1369-14.9423) 0.0311a
Gender (male/female) 0.9989   
Location (middle, lower/upper) 0.1605   
Differentiation (not poorly/poorly) 0.6711   
cT (T3-4/T1-2) 0.9991   
cN (N2-3/N1) 0.7055   
cM (M1 (lymph node)/M0) 0.4804   
pT (T3-4/T1-2) 0.2130   
pN (N2-3/N1) 0.0965   
SUVmax reduction rate in the primary lesion (<60%/≥60%) 0.0007a 8.3800 (2.3893–29.3915) 0.0009a
DSS
Age ( ≥65/<65) 0.0246a 5.2678 (1.2729–21.8008) 0.0219a
Gender (male/female) 0.9990   
Location (middle, lower/upper) 0.2356   
Differentiation (not poorly/poorly) 0.9992   
cT (T3-4/T1-2) 0.9992   
cN (N2-3/N1) 0.3436   
cM (M1 (lymph node)/M0) 0.3277   
pT (T3-4/T1-2) 0.4104   
pN (N2-3/N1) 0.0969   
SUVmax reduction rate in the primary lesion (<60%/≥60%) 0.0034a 7.6048 (1.9819–29.1798) 0.0031a
RFS
Age (≥65/<65) 0.1947   
Gender (male/female) 0.2876   
Location (middle, lower/upper) 0.0759   
Differentiation (not poorly/poorly) 0.2910   
cT (T3-4/T1-2) 0.9203   
cN (N2-3/N1) 0.4032   
cM (M1 (lymph node)/M0) 0.7506   
pT (T3-4/T1-2) 0.0312a 2.5857 (0.8313–8.0423) 0.1008
pN (N2-3/N1) 0.0330a 0.6968 (0.1794–2.7072) 0.6019
SUVmax reduction rate in the primary lesion (<60%/≥60%) 0.0006a 6.2962 (1.4981–26.4625) 0.0120a
  1. OS overall survival, DSS disease-specific survival, RFS relapse-free survival, HR hazard ratio, CI confidence interval
  2. *Statistically significant